Clinical Trial Update: Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase I trial evaluating a combination of midostaurin and bortezomib with chemotherapy in relapsed/refractory acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Del
• Acute Myeloid Leukemia with Inv
• Acute Myeloid Leukemia with Multilineage Dysplasia
• Myelodysplastic Syndrome

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• Chemotherapy (chemotherapy)
• Midostaurin (Rydapt) (midostaurin)

Snippet

Sponsor: Alison Walker | Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following | Phase 1 | Status: COMPLETED